Stroke: Measuring disease-free life after thrombolysis

Nature Reviews Neurology

Volumn 6, Issue 7, 2010, Pages 361-362

  Fagan, Susan C ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISABILITY ADJUSTED LIFE YEAR; DISABILITY SEVERITY; DRUG EFFICACY; HEALTH CARE COST; HUMAN; PATIENT DECISION MAKING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SHORT SURVEY; TREATMENT OUTCOME; COHORT ANALYSIS; COMPLICATION; DISABILITY; FIBRINOLYTIC THERAPY; STROKE;

BRAIN ISCHEMIA; COHORT STUDIES; DISABILITY EVALUATION; HUMANS; PLASMINOGEN ACTIVATORS; QUALITY-ADJUSTED LIFE YEARS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77954845349     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.79     Document Type: Short Survey

References (6)

1. Hong, K. S. & Saver, J. L. Years of disabilityadjusted life gained as a result of thrombolytic therapy for acute ischemic stroke. Stroke 41, 471-477 (2010).
2. [no authors listed] Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological Disorders and stroke rt-PA stroke study Group. N. Engl. J. Med. 333, 1581-1587 (1995).
3. Dachs, R. J., Burton, J. H. & Joslin, J. A user's guide to the ninDs rt-PA stroke trial database. PLoS Med. 5, e113 (2008).
4. Slot, K. B. et al. impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies. BMJ 336, 376-379 (2008).
5. Eriksson, M., norrving, B., Terent, A. & stegmayr, B. Functional outcome 3 months after stroke predicts long term survival. Cerebrovasc. Dis. 25, 423-429 (2008).
6. Fagan, s. C. et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 50, 883-890 (1998).